168 related articles for article (PubMed ID: 20563626)
21. Treatment of experimental pancreatic cancer by doxorubicin-, mitoxantrone-, and irinotecan-drug eluting beads.
Yagublu V; Caliskan N; Lewis AL; Jesenofsky R; Gasimova L; Löhr JM; Keese M
Pancreatology; 2013; 13(1):79-87. PubMed ID: 23395574
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical trial of weekly combined topotecan and irinotecan.
Lokich J
Am J Clin Oncol; 2001 Aug; 24(4):336-40. PubMed ID: 11474256
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of ion exchange processes in drug-eluting embolization beads by use of an improved flow-through elution method.
Swaine T; Tang Y; Garcia P; John J; Waters LJ; Lewis AL
Eur J Pharm Sci; 2016 Oct; 93():351-9. PubMed ID: 27523788
[TBL] [Abstract][Full Text] [Related]
24. Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series.
Jones RP; Dunne D; Sutton P; Malik HZ; Fenwick SW; Terlizzo M; O'Grady E; Koelblinger C; Stättner S; Stremitzer S; Gruenberger T; Poston GJ
HPB (Oxford); 2013 Jan; 15(1):71-7. PubMed ID: 23216781
[TBL] [Abstract][Full Text] [Related]
25. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
Richardson AJ; Laurence JM; Lam VW
J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
[TBL] [Abstract][Full Text] [Related]
26. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution.
Lewis AL; Gonzalez MV; Leppard SW; Brown JE; Stratford PW; Phillips GJ; Lloyd AW
J Mater Sci Mater Med; 2007 Sep; 18(9):1691-9. PubMed ID: 17483878
[TBL] [Abstract][Full Text] [Related]
28. Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases.
Tang Y; Czuczman PR; Chung ST; Lewis AL
J Control Release; 2008 Apr; 127(1):70-8. PubMed ID: 18237814
[TBL] [Abstract][Full Text] [Related]
29. Compatibility of irinotecan-loaded DC Bead with different volumes and types of non-ionic contrast media.
Sarakbi I; Thiesen J; Krämer I
Eur J Hosp Pharm; 2016 Jan; 23(1):38-43. PubMed ID: 31156812
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the plasmatic and parenchymal elution kinetics of two different irinotecan-loaded drug-eluting embolics in a pig model.
Gnutzmann DM; Mechel J; Schmitz A; Köhler K; Krone D; Bellemann N; Gockner TL; Mokry T; Kortes N; Sommer CM; Kauczor HU; Radeleff BA; Stampfl U
J Vasc Interv Radiol; 2015 May; 26(5):746-54. PubMed ID: 25704223
[TBL] [Abstract][Full Text] [Related]
31. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI).
Eichler K; Zangos S; Mack MG; Hammerstingl R; Gruber-Rouh T; Gallus C; Vogl TJ
Int J Oncol; 2012 Oct; 41(4):1213-20. PubMed ID: 22842404
[TBL] [Abstract][Full Text] [Related]
32. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results.
Aliberti C; Tilli M; Benea G; Fiorentini G
Anticancer Res; 2006; 26(5B):3793-5. PubMed ID: 17094403
[TBL] [Abstract][Full Text] [Related]
33. Loading, release and stability of epirubicin-loaded drug-eluting beads.
Spindeldreier KC; Thiesen J; Krämer I
J Oncol Pharm Pract; 2016 Aug; 22(4):591-8. PubMed ID: 26160072
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation.
Gonzalez MV; Tang Y; Phillips GJ; Lloyd AW; Hall B; Stratford PW; Lewis AL
J Mater Sci Mater Med; 2008 Feb; 19(2):767-75. PubMed ID: 17653626
[TBL] [Abstract][Full Text] [Related]
35. Doxorubicin-loaded drug-eluting beads (DC Bead®) for use in transarterial chemoembolization: a stability assessment.
Hecq JD; Lewis AL; Vanbeckbergen D; Athanosopoulos A; Galanti L; Jamart J; Czuczman P; Chung T
J Oncol Pharm Pract; 2013 Mar; 19(1):65-74. PubMed ID: 22801955
[TBL] [Abstract][Full Text] [Related]
36. Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study.
Boeken T; Moussa N; Pernot S; Abed A; Dean C; Taieb J; Sapoval M; Pellerin O
Cardiovasc Intervent Radiol; 2020 Jun; 43(6):866-874. PubMed ID: 32103303
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.
Glage S; Lewis AL; Mertens P; Baltes S; Geigle P; Brinker T
Clin Transl Oncol; 2012 Jan; 14(1):50-9. PubMed ID: 22262719
[TBL] [Abstract][Full Text] [Related]
38. Bradycardia associated with drug-eluting beads loaded with irinotecan (DEBIRI) infusion for colorectal liver metastases.
Pua U
Cardiovasc Intervent Radiol; 2013 Jun; 36(3):864-6. PubMed ID: 22722719
[TBL] [Abstract][Full Text] [Related]
39. Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
Akinwande O; Scoggins C; Martin RC
Anticancer Res; 2016 Jul; 36(7):3413-8. PubMed ID: 27354601
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.
Keese M; Gasimova L; Schwenke K; Yagublu V; Shang E; Faissner R; Lewis A; Samel S; Löhr M
Int J Cancer; 2009 Jun; 124(11):2701-8. PubMed ID: 19165866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
